









Markets
/
Stocks
/
nasdaq-pdsb
/

PDS Biotechnology Corp

PDSB

0.715USD

+0.025+3.59%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

34.11MMarket Cap

LossP/E TTM



PDS Biotechnology Corp

0.715

+0.025+3.59%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of PDS Biotechnology Corp

Currency: USD Updated: 2026-02-06

Key Insights

PDS Biotechnology Corp's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 170 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 7.50.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

PDS Biotechnology Corp's Score

Industry at a Glance

Industry Ranking

170 / 392

Overall Ranking

322 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

PDS Biotechnology Corp Highlights

StrengthsRisks

PDS Biotechnology Corporation is a clinical-stage immunotherapy company. The Company is developing a pipeline of targeted cancer immunotherapies based on its Versamune T cell-activator and Versamune in combination with its interleukin 12 (IL-12) fused antibody drug conjugate (ADC), PDS01ADC, a tumor targeting immunocytokine. PDS0101 is its lead Versamune based immunotherapy. PDS0101 combines Versamune with a mixture of short proteins (peptides) derived from the cancer-causing HPV16 viral protein. Versamune is a proprietary lipid nanoparticle and T cell activating platform. PDS0301 is an investigational tumor-targeting antibody conjugate of Interleukin 12 (IL-12) that enhances the proliferation, potency, infiltration, and longevity of T cells in the tumor microenvironment. Its Versamune immunotherapies and Versamune in combination with PDS01ADC, are utilized for treatments in oncology, and Infectimune is utilized for preventive vaccines against infectious agents.

Overvalued

The company’s latest PE is -0.88, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 5.60M shares, decreasing 42.29% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 1.95M shares of this stock.

Analyst Rating

Based on 3 analysts

Buy

Current Rating

7.500

Target Price

+927.26%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of PDS Biotechnology Corp is 7.09, ranking 160 out of 392 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

7.09

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.69

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

PDS Biotechnology Corp's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of PDS Biotechnology Corp is 7.55, ranking 102 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.88, which is -3.47% below the recent high of -0.85 and -855.08% above the recent low of -8.39.

Score

Industry at a Glance

Previous score

7.55

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 170/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of PDS Biotechnology Corp is 8.00, ranking 164 out of 392 in the Biotechnology & Medical Research industry. The average price target is 4.50, with a high of 15.00 and a low of 3.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 3 analysts

Buy

Current Rating

7.500

Target Price

+927.26%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

PDS Biotechnology Corp

PDSB

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Beigene Ltd

ONC

Intellia Therapeutics Inc

NTLA

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of PDS Biotechnology Corp is 4.47, ranking 347 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 1.02 and the support level at 0.55, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

4.42

Change

0.05

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(1)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.054

Sell

RSI(14)

32.845

Neutral

STOCH(KDJ)(9,3,3)

7.858

Oversold

ATR(14)

0.078

High Vlolatility

CCI(14)

-128.006

Sell

Williams %R

90.371

Oversold

TRIX(12,20)

-0.565

Sell

StochRSI(14)

36.094

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

0.745

Sell

MA10

0.814

Sell

MA20

0.891

Sell

MA50

0.883

Sell

MA100

0.919

Sell

MA200

1.119

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of PDS Biotechnology Corp is 3.00, ranking 197 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 10.70%, representing a quarter-over-quarter decrease of 34.81%. The largest institutional shareholder is The Vanguard, holding a total of 1.95M shares, representing 3.73% of shares outstanding, with 11.97% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

1.90M

-2.56%

Bedu-Addo (Frank)

690.87K

BlackRock Institutional Trust Company, N.A.

508.21K

+0.62%

Geode Capital Management, L.L.C.

482.00K

+15.33%

Sykes (Richard)

445.11K

Citadel Advisors LLC

386.43K

+55.18%

Squarepoint Capital LLP

291.63K

+198.29%

Renaissance Technologies LLC

Star Investors

275.86K

+161.02%

UBS Financial Services, Inc.

86.26K

-79.67%

William Blair & Company, L.L.C. (Research)

250.00K

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. No risk assessment score is currently available for PDS Biotechnology Corp. The Biotechnology & Medical Research industry's average is 3.38. The company's beta value is 1.18. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. PDS Biotechnology Corp’s latest ESG disclosure leads the Biotechnology & Medical Research industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.